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While the exact mechanisms behind the relationship 
between elevated soluble vascular endothelial cell growth 
factor receptor-1 (sVEGFR-1) levels and clinical outcome 
remain controversial, the ﬁ  nding in the current study by 
Yang and colleagues [1] that sVEGFR-1 is a promising 
sepsis biomarker is quite consistent with previous studies 
[2,3]. In fact, in a recent investigation, we demonstrated 
that sVEGFR-1 performed with a diagnostic accuracy 
equal to, or exceeding, that of the commonly used sepsis 
biomarkers interleukin-6 and serum lactate [3]. 
Interestingly, preclinical studies have demonstrated that 
sepsis induces elevated levels of vascular endothelial cell 
growth factor (VEGF), as well as elevated levels of 
sVEGFR-1 [4,5]. Th  ese studies have shown that VEGF 
exacerbates sepsis and mediates morbidity and mortality, 
while it is thought that circulating sVEGFR-1 binds and 
neutralizes the adverse/pro-inﬂ  ammatory  eﬀ  ects  of 
VEGF. Th  is hypothesis is supported by the observation 
that supratherapeutic levels of sVEGFR-1 in murine 
models of sepsis deplete the blood of free VEGF and 
protect against morbidity and mortality.
If sVEGFR-1 is protective, then why are elevated 
circulating levels of sVEGFR-1 associated with worse 
clinical outcome in sepsis? Th   e apparent dichotomy may 
be explained by one or more of the following hypotheses: 
1, sVEGFR-1 levels simply reﬂ  ect the vigor of the anti-
inﬂ  ammatory response in sepsis (akin to policeman at 
the scene of a crime - likely the more policeman, the 
worse the crime); 2, elevated sVEGFR-1 may cause pro-
found immune depression by interfering with sVEGFR-1-
mediated signaling in monocytes; and 3, sVEGFR-1 may 
interfere with endothelial repair by inhibiting VEGF 
signaling in endothelial cells.
As Yang and colleagues point out, the existing literature 
concerning circulating VEGF levels in sepsis is contro-
versial. Previous studies have shown that adverse out-
comes in sepsis are associated with either high [2,6,7] or 
low [8] VEGF levels. In the current study, VEGF levels 
did not predict adverse clinical outcomes. However, it 
should be noted that the investigation used total VEGF 
levels, which is diﬀ  erent than measuring physiologically 
active free or unbound VEGF. Additionally, obtaining 
reproducible VEGF measurements is notoriously diﬃ   -
cult. In any event, the diagnostic value of VEGF remains 
circumspect. However, given the biological plausibility of 
a pathogenic role for VEGF in sepsis pathophysiology (by 
virtue of its pro-inﬂ  ammatory, permeability-promoting 
and procoagulant eﬀ  ects at the level of the endothelium) 
we believe that the VEGF signaling axis remains a viable 
therapeutic target. To test this hypothesis, we are 
currently investigating the use of an anti-VEGF antibody 
in patients with septic shock (clinicaltrials.gov identiﬁ  er 
NCT01063010).
Finally, we submit that while the exact mechanisms 
governing the observed association between urokinase-
type plasminogen activator (uPA) and outcomes in this 
study is unknown, the presence of this association 
Abstract
The study by Yang and colleagues examined 81 
patients with septic shock due to pneumonia, along 
with 20 patients with pneumonia without organ 
dysfunction. Their major fi  ndings were that circulating 
levels of soluble vascular endothelial cell growth factor 
receptor-1 (sVEGFR-1) and urokinase-type plasminogen 
activator (uPA) were associated with organ dysfunction 
and mortality, whereas vascular endothelial cell 
growth factor (VEGF) levels had no such predictive 
power. Yang and colleagues are to be complimented 
for a well-conducted study of a reasonably (and 
helpfully!) homogeneous population of patients with 
sepsis that carefully and comprehensively analyzed 
the relationship between sVEGFR-1, uPA, VEGF and 
clinical outcome. The study serves not only to provide 
evidence in support of new diagnostic biomarker 
targets in sepsis, but also to augment the growing 
evidence of an important role of the endothelium 
in sepsis in general, and the VEGF signaling axis in 
particular.
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© 2011 BioMed Central Ltdunder  scores the importance and dynamic role of the 
endo  the  lium in sepsis. Th   e conversion of plasminogen to 
plasmin, which is primarily governed by uPA, occurs at 
the level of the endothelium and is a primary regulator of 
the hemo  static balance in sepsis. As the evidence for a 
central role of the endothelium in sepsis builds, it is likely 
that a number of other endothelial-related biomarkers 
will emerge that reﬂ  ect a ‘broken endothelium’. Perhaps 
one or more of these markers can be leveraged in future 
trials to guide therapy with novel yet-to-be-determined 
endothelium-sparing agents.
Abbreviations
sVEGFR-1, soluble vascular endothelial cell growth factor receptor-1; uPA, 
urokinase-type plasminogen activator; VEGF, vascular endothelial cell growth 
factor.
Competing interests
The authors declare that they have no competing interests.
Author details
1Department of Emergency Medicine, Center for Vascular Biology Research, 
Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. 2Department of 
Medicine, Center for Vascular Biology Research, Beth Israel Deaconess Medical 
Center, Boston, MA 02215, USA.
Published: 21 March 2011
References
1.  Yang KY, Liu KT, Chen YC, Chen CS, Lee YC, Perng RP, Feng JY: Plasma soluble 
vascular endothelial growth factor receptor-1 levels predict outcomes of 
pneumonia-related septic shock patients: a prospective observational 
study. Crit Care 2011, 15:R11.
2.  Shapiro NI, Yano K, Okada H, Fischer C, Howell M, Spokes KC, Ngo L, Angus 
DC, Aird WC: A prospective, observational study of soluble FLT-1 and 
vascular endothelial growth factor in sepsis. Shock 2008, 29:452-457.
3.  Shapiro NI, Schuetz P, Yano K, Sorasaki M, Parikh SM, Jones AE, Trzeciak S, Ngo 
L, Aird WC: The association of endothelial cell signaling, severity of illness, 
and organ dysfunction in sepsis. Crit Care 2010, 14:R182.
4.  Yano K, Liaw PC, Mullington JM, Shih SC, Okada H, Bodyak N, Kang PM, Toltl L, 
Belikoff   B, Buras J, Simms BT, Mizgerd JP, Carmeliet P, Karumanchi SA, Aird WC: 
Vascular endothelial growth factor is an important determinant of sepsis 
morbidity and mortality. J Exp Med 2006, 203:1447-1458.
5.  Tsao PN, Chan FT, Wei SC, Hsieh WS, Chou HC, Su YN, Chen CY, Hsu WM, Hsieh 
FJ, Hsu SM: Soluble vascular endothelial growth factor receptor-1 protects 
mice in sepsis. Crit Care Med 2007, 35:1955-1960.
6.  Pickkers P, Sprong T, Eijk LV, Hoeven HV, Smits P, Deuren MV: Vascular 
endothelial growth factor is increased during the fi  rst 48 hours of human 
septic shock and correlates with vascular permeability. Shock 2005, 
24:508-512.
7.  van der Flier M, van Leeuwen HJ, van Kessel KP, Kimpen JL, Hoepelman AI, 
Geelen SP: Plasma vascular endothelial growth factor in severe sepsis. 
Shock 2005, 23:35-38.
8.  Mankhambo LA, Banda DL; IPD Study Group, Jeff  ers G, White SA, Balmer P, 
Nkhoma S, Phiri H, Molyneux EM, Hart CA, Molyneux ME, Heyderman RS, 
Carrol ED: The role of angiogenic factors in predicting clinical outcome in 
severe bacterial infection in Malawian children. Crit Care 2010, 14:R91.
doi:10.1186/cc10044
Cite this article as: Shapiro NI, Aird WC: Sepsis and the broken endothelium. 
Critical Care 2011, 15:135.
Shapiro and Aird Critical Care 2011, 15:135 
http://ccforum.com/content/15/2/135
Page 2 of 2